Poor
Needs Revision
Patient Risk:
Moderate
Summary
The claims substantially exceed or mischaracterize the FDA prescribing information. Only the statement that patients receiving Cosentyx should avoid live vaccines is directly supported. The label does not contain a vaccine-related boxed warning, does not specify post-treatment avoidance periods or a waiting interval, and does not recommend pausing Cosentyx before vaccination.
Category Scores
Accurate Statements
Novartis indicates that patients should not receive live vaccines during Cosentyx treatment.
Consistent with Warnings and Precautions, section 5.7, Immunizations, which states that patients receiving Cosentyx should avoid live vaccines.
Unsupported Statements
Cosentyx's biologics license application was approved under section 505(b)(2) of the Food, Drug, and Cosmetic Act.
The supplied FDA prescribing information does not state approval under section 505(b)(2), and the claim is not supported by the label.
The European Medicines Agency recommends caution when administering live vaccines to patients receiving Cosentyx.
This is an EMA-related statement and is not supported by the supplied FDA label.
The European Medicines Agency advises that patients receiving Cosentyx may need to wait before receiving live vaccines.
The FDA label does not provide an EMA recommendation or specify a waiting period before live vaccination.
The exact duration of the wait before receiving a live vaccine is not specified.
The FDA label does not recommend a waiting period or Cosentyx interruption interval for live vaccines.
Novartis indicates that patients should not receive live vaccines for certain periods after Cosentyx treatment.
The FDA label does not specify post-treatment periods during which live vaccines should be avoided.
The duration of any Cosentyx pause before live vaccination should be determined on a case-by-case basis.
The FDA label provides no case-by-case interruption recommendation or duration for holding Cosentyx before live vaccination.
Contradictions
High
AI Statement
The approval includes a condition requiring a boxed warning about potential effects on live or inactivated vaccines.
Label Reference
Warnings and Precautions, section 5.7, Immunizations
Moderate
AI Statement
Patients taking Cosentyx should take precautions or pause the medication before receiving live vaccines.
Label Reference
Warnings and Precautions, section 5.7, Immunizations
Important Omissions
The label advises completion of age-appropriate immunizations before initiating Cosentyx treatment.
Importance:
Moderate
The label specifically states that patients receiving Cosentyx should avoid live vaccines, without providing a post-treatment waiting period or medication-interruption interval.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The response correctly identifies avoidance of live vaccines during treatment but adds unsupported waiting-period and medication-pause guidance and incorrectly describes a vaccine-related boxed warning. These statements could create inaccurate expectations about vaccination timing and Cosentyx interruption.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
The response attributes unsupported EMA and Novartis recommendations to the FDA label and incorrectly states that Cosentyx has a vaccine-related boxed warning and a recommended pause or waiting period.
Suggested Improvement
Limit the discussion to the FDA label: complete age-appropriate immunizations before treatment and avoid live vaccines while receiving Cosentyx. Do not add a boxed-warning characterization, post-treatment interval, or recommendation to pause treatment unless supported by the label.